PL3646854T3 - Kompozycje do transfekcji mrna do komórki i ich zastosowania - Google Patents
Kompozycje do transfekcji mrna do komórki i ich zastosowaniaInfo
- Publication number
- PL3646854T3 PL3646854T3 PL18306417.9T PL18306417T PL3646854T3 PL 3646854 T3 PL3646854 T3 PL 3646854T3 PL 18306417 T PL18306417 T PL 18306417T PL 3646854 T3 PL3646854 T3 PL 3646854T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- applications
- cell
- transfecting mrna
- transfecting
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18306417.9A EP3646854B1 (en) | 2018-10-30 | 2018-10-30 | Compositions for transfecting mrna into a cell and their applications |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3646854T3 true PL3646854T3 (pl) | 2023-01-02 |
Family
ID=64572258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL18306417.9T PL3646854T3 (pl) | 2018-10-30 | 2018-10-30 | Kompozycje do transfekcji mrna do komórki i ich zastosowania |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210386841A1 (pl) |
EP (1) | EP3646854B1 (pl) |
JP (1) | JP2022512983A (pl) |
KR (1) | KR20210084511A (pl) |
CN (1) | CN112930172B (pl) |
AU (1) | AU2019373387A1 (pl) |
CA (1) | CA3113877A1 (pl) |
DK (1) | DK3646854T3 (pl) |
ES (1) | ES2927532T3 (pl) |
IL (1) | IL282579A (pl) |
PL (1) | PL3646854T3 (pl) |
PT (1) | PT3646854T (pl) |
SG (1) | SG11202103117RA (pl) |
WO (1) | WO2020089342A1 (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022006534A2 (pt) | 2019-10-24 | 2022-07-05 | Novago Therapeutics Ag | Anticorpos anti-nogo-a |
WO2021245184A1 (en) | 2020-06-02 | 2021-12-09 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
WO2024003363A1 (en) * | 2022-06-30 | 2024-01-04 | Universiteit Gent | Cationic amphiphilic compound-based nanoparticle compositions |
WO2024008967A1 (en) | 2022-07-08 | 2024-01-11 | Polyplus Transfection | Lipid nanoparticles comprising an imidazolium-based cationic lipid |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5627159A (en) | 1994-10-27 | 1997-05-06 | Life Technologies, Inc. | Enhancement of lipid cationic transfections in the presence of serum |
FR2732895B1 (fr) * | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament |
ATE383331T1 (de) | 1998-11-12 | 2008-01-15 | Invitrogen Corp | Transportreagentien |
EP1844772A1 (en) | 2006-04-06 | 2007-10-17 | Polyplus-Transfection SA | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
EP2860255A1 (en) * | 2013-10-14 | 2015-04-15 | Technische Universität Graz | Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells |
CN106572974B (zh) * | 2014-07-15 | 2021-04-23 | 生命技术公司 | 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法 |
JP6731912B2 (ja) * | 2014-09-05 | 2020-07-29 | ノバルティス アーゲー | 活性物質の送達用の脂質および脂質組成物 |
PL3373910T3 (pl) * | 2015-11-10 | 2023-10-09 | Children's Research Institute, Children's National Medical Center | Preparat echinomycyny, sposób wytwarzania i sposób stosowania |
-
2018
- 2018-10-30 PL PL18306417.9T patent/PL3646854T3/pl unknown
- 2018-10-30 ES ES18306417T patent/ES2927532T3/es active Active
- 2018-10-30 DK DK18306417.9T patent/DK3646854T3/da active
- 2018-10-30 EP EP18306417.9A patent/EP3646854B1/en active Active
- 2018-10-30 PT PT183064179T patent/PT3646854T/pt unknown
-
2019
- 2019-10-30 JP JP2021525178A patent/JP2022512983A/ja active Pending
- 2019-10-30 CA CA3113877A patent/CA3113877A1/en active Pending
- 2019-10-30 CN CN201980071624.3A patent/CN112930172B/zh active Active
- 2019-10-30 US US17/289,443 patent/US20210386841A1/en active Pending
- 2019-10-30 KR KR1020217015096A patent/KR20210084511A/ko unknown
- 2019-10-30 AU AU2019373387A patent/AU2019373387A1/en active Pending
- 2019-10-30 SG SG11202103117RA patent/SG11202103117RA/en unknown
- 2019-10-30 WO PCT/EP2019/079742 patent/WO2020089342A1/en active Application Filing
-
2021
- 2021-04-22 IL IL282579A patent/IL282579A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3113877A1 (en) | 2020-05-07 |
CN112930172B (zh) | 2023-12-22 |
CN112930172A (zh) | 2021-06-08 |
EP3646854A1 (en) | 2020-05-06 |
IL282579A (en) | 2021-06-30 |
ES2927532T3 (es) | 2022-11-08 |
US20210386841A1 (en) | 2021-12-16 |
JP2022512983A (ja) | 2022-02-07 |
WO2020089342A1 (en) | 2020-05-07 |
AU2019373387A1 (en) | 2021-04-29 |
PT3646854T (pt) | 2022-09-27 |
SG11202103117RA (en) | 2021-04-29 |
DK3646854T3 (da) | 2022-09-26 |
KR20210084511A (ko) | 2021-07-07 |
EP3646854B1 (en) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282735A (en) | Preparations and methods for t-cell engineering | |
IL282579A (en) | Mixtures for mRNA transfection into cells and their applications | |
SG11202004116QA (en) | T cell manufacturing compositions and methods | |
EP4083067A4 (en) | CD7-CAR-T CELL, ITS PREPARATION AND ITS USE | |
IL280935A (en) | Modified plant messenger packages and their uses | |
GB201813178D0 (en) | Cell | |
EP3519578A4 (en) | COMPOSITIONS FOR TRANSFECTION OF RESISTANT CELL TYPES | |
IL277673A (en) | Transgenic cells and their uses | |
IL287874A (en) | Preparations and methods for producing t cells | |
GB201803079D0 (en) | Cell | |
IL290398A (en) | Material transfer systems and methods | |
EP3813856A4 (en) | CELL COMPOSITIONS AND USES THEREOF | |
IL282160A (en) | Preparations and methods for transferring genes between cells | |
IL270719A (en) | Biopharmaceutical compounds and related methods | |
GB201819540D0 (en) | T cell modification | |
IL281531A (en) | Cells produce insulin | |
EP3527932A4 (en) | THICKNESS GAUGE FOR BATTERY MATERIAL | |
IL273247A (en) | New cell row and its uses | |
EP3787688A4 (en) | COMPOSITIONS FOR TRANSFECTION OF RESISTANT CELL TYPES | |
EP3710470A4 (en) | IMMUNOREACTIVE CELLS SECRETING IL-33 AND THEIR USES | |
GB201807693D0 (en) | Cell | |
GB201803363D0 (en) | New materials and uses thereof | |
IL290109A (en) | Cells for enhanced immune healing and their uses | |
EP3795673A4 (en) | CELL FRAMEWORK MATERIAL | |
GB201915526D0 (en) | Modified cell |